Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

News

Johnson & Johnson's fair value intact despite talc powder risks

Lex Hall  |  19 Dec 2018Text size  Decrease  Increase  |  
Email to Friend

The diversity of its operations and a pipeline of blockbuster products will help US healthcare giant Johnson & Johnson withstand a baby powder scandal that has buffeted its share price, says Morningstar.

J&J, the world's largest healthcare products maker, is facing more than 6000 cases related to the use of its talcum powder causing personal injury, in many instances cancer, says Morningstar US analyst Damien Conover.

While close to half these verdicts have gone against J&J, Conover says the company has established a fighting fund in anticipation of further litigation.

Johnson & Johnson healthcare talcum powder

Johnson & Johnson's shares fell 1.3 per cent on news of the settlement

Despite a 10 per cent fall in its share price in the wake of the latest case, its biggest fall since 2002, J&J retains its fair value estimate and wide moat, Conover says.

He was speaking a few days before the latest case in which J&J and its talc supplier Imerys reportedly agreed to pay a $1.5 million settlement to a 78-year-old Manhattan woman, who had claimed the well-known product caused asbestos cancer.

In the New York case, set to go on trial early next month in state court, J&J's lawyers will argue that Ann Zoas contracted mesothelioma from smoking, not baby powder, Bloomberg reported.

J&J's shares fell 1.3 per cent on news of the settlement. It's currently trading at $130.42, in line with Morningstar's $130 fair value estimate.

J&J has steadfastly denied its baby powder contains asbestos.

In his 15 December note, Conover said the bulk of the asbestos-related cases were motivated by trying to link an unrelated disease to talc powder use, in a bid to gain a settlement from J&J.

"We believe J&J's rigorous testing over the years will provide legal protection against the majority of these case," he said.

"By litigating these cases one by one, we expect J&J will wear down the plaintiff group, ending with a settlement that does not cause a major impact to the company’s stock price." 

Conover notes that J&J has previously withstood settlements when it faced lawsuits over its metal-on-metal prosthetic hips.

In a note earlier this year, Conover said J&J had one of the widest moats – a measure of sustainable competitive advantage – in the healthcare sector.

This is supported by intellectual property in its drug group, switching costs in the device segment, and strong brand power.

The company's research and development efforts are also leading to "next-generation" products, which is boosted by strong cash flow, Conover said.

"The pharmaceutical group has recently launched several new blockbusters. However, relative to the company's size, J&J needs to increase the number of meaningful drugs in late-stage development to support long-term growth," he said in April.

"The company has also created new medical devices, including innovative contact lenses and minimally invasive surgical tools.

"These multiple businesses generate substantial cash flow. J&J's healthy free cash flow is over 20 per cent of sales. Strong cash generation has enabled the firm to increase its dividend for over the past half century, and we expect this to continue."

 

is content editor for Morningstar Australia

© 2020 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Any general advice or 'class service' have been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/s/fsg.pdf. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a licensed financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782. The article is current as at date of publication.

Email To Friend